Posts

Posted on

Cigna Announces Leadership Changes to Accelerate Next Phase of Growth

– Eric Palmer becomes president and chief operating officer of Evernorth

– Brian Evanko becomes chief financial officer of Cigna Corporation

– Matt Manders assumes leadership of government business as president, government and solutions of Cigna Corporation

– Everett Neville promoted to executive vice president, strategy and business development of Cigna Corporation

– Aparna Abburi promoted to president, Medicare

– Amy Bricker promoted to president, Express Scripts

PR Newswire

BLOOMFIELD, Conn., Dec. 10, 2020 /PRNewswire/ — Cigna Corporation (NYSE: CI) today announced leadership changes designed to accelerate the company’s growth through its two power brands, Cigna and Evernorth. Effective Jan. 1, 2021, Eric Palmer will become the president and chief operating officer of Evernorth; Brian Evanko will become executive vice president and chief financial officer of Cigna Corporation; Matt Manders will assume the role of president, government and solutions of Cigna Corporation; Everett Neville will assume the role of executive vice president, strategy and business development of Cigna Corporation; Aparna Abburi will assume the role of president, Medicare; and Amy Bricker will assume the role of president, Express Scripts.

“The depth and breadth of our leadership talent are a key strength of our organization,” said David M. Cordani, president and chief executive officer, Cigna Corporation. “These leaders have a track record of driving growth, and a relentless focus on supporting the diverse needs of all those we serve around the world by delivering on our promise of making health care more affordable, predictable, and simple. I am pleased that our long-standing commitment to talent development allows us to strategically place our seasoned team of leaders in key positions that will maximize value-creation and value-generation for our customers, clients, and shareholders.”


Eric Palmer named president and chief operating officer of Evernorth

Palmer has been named president and chief operating officer of Evernorth. In this new role, Palmer will have oversight of Evernorth’s pharmacy services, care management services and benefit management services. He will remain a member of Cigna Corporation’s enterprise leadership team, and will report to Tim Wentworth, chief executive officer of Evernorth.

Palmer joined the company in 1998, and currently serves as chief financial officer. Over the course of his more than 22 years at Cigna, Palmer has held multiple key finance and actuarial leadership roles, and contributed to the success of the combination of Cigna and Express Scripts, as well as the launch of Evernorth. Palmer’s market perspective, deep business experience and focus on value creation make him uniquely suited to lead Evernorth operations through its new and exciting chapter of growth.


Brian Evanko named executive vice president and chief financial officer of Cigna

Evanko has been named the new chief financial officer of Cigna Corporation. As CFO, Evanko will assume leadership for all of Cigna Corporation’s financial operations and functions, including the company’s investment management and underwriting units. He will continue to report to David Cordani. 

Evanko joined Cigna in 1998, and currently serves as president, government business, where he led the growth strategy for each of its businesses. Evanko has held multiple key leadership roles over the span of his 22-year Cigna career, including serving as business financial officer for Cigna’s global individual operations.


Matt Manders assumes oversight of government business

Manders is assuming an expanded leadership role as president, government and solutions for Cigna Corporation. In addition to oversight of Cigna Solutions, Manders will lead Cigna’s U.S. government business segment, including all Medicare, Individual, and Medicaid product offerings.

Over his 30-year career with Cigna, Manders has served in a variety of key commercial and strategic leadership roles in the U.S. and abroad, including previously serving as president, government and individual programs. His experience at the helm of multiple Cigna businesses and functions will support the continued rapid growth of the government businesses.


Everett Neville named executive vice president, strategy and business development

Neville has been named executive vice president, strategy and business development. In this new role, Neville will have oversight of Cigna Corporation’s strategy, corporate development, business development, and Cigna Ventures. Reporting to David Cordani, he will become a member of Cigna Corporation’s enterprise leadership team.

A pharmacist by training, Neville joined Cigna’s Express Scripts business in 1998. He most recently served as senior vice president, value creation for Cigna Corporation. Over the span of his career with Express Scripts, he held leadership roles in supply chain and in the health plan division.


Aparna Abburi promoted to president, Medicare business

Abburi has been named president, Medicare.  In this role, Abburi will continue leading Cigna’s Medicare Advantage business, and will also assume oversight of Cigna Supplemental Benefits and Government Pharmacy. 

Abburi joined Cigna in July, 2020, from Health Care Services Corporation (HCSC), where she served as president of the Medicare business. 


Amy Bricker promoted to president, Express Scripts business

Bricker has been named president, Express Scripts. Bricker’s responsibilities will expand from leading supply chain and drug procurement, to leadership for all of Evernorth’s pharmacy benefit management (PBM) services. 

Over the past decade with Express Scripts, Bricker, a pharmacist by training, has served in a variety of key leadership roles in pharmacy network management, supply chain economics, and retail contracting and strategy.

About Cigna

Cigna Corporation is a global health service company dedicated to improving the health, well-being and peace of mind of those we serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna Life Insurance Company of New York, Connecticut General Life Insurance Company, Evernorth companies or their affiliates, Express Scripts companies or their affiliates, and Life Insurance Company of North America. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and other related products. Cigna maintains sales capability in over 30 countries and jurisdictions, and has approximately 190 million customer relationships throughout the world. To learn more about Cigna®, including links to follow us on Facebook or Twitter, visit www.cigna.com.

About Evernorth

Evernorth is the brand for Cigna’s growing, high-performing health services portfolio. The Evernorth brand is anchored by Evernorth Health, Inc., a wholly-owned subsidiary of Cigna Corporation, and the parent company of the Express Scripts, Accredo, and eviCore companies. Evernorth brings together and coordinates premier health services offerings to deliver innovative and flexible solutions for health plans, employers, and government programs. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health or third-party partners. To learn more about Evernorth, visit www.Evernorth.com.

Media Contact

Jim Cohn

[email protected]

Or       

Investor Relations Contact

Alexis Jones

[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cigna-announces-leadership-changes-to-accelerate-next-phase-of-growth-301190013.html

SOURCE Cigna

Posted on

Former Seattle Police Chief to Join Axon’s AI Ethics Board, Promoting Responsible Development of AI Technologies

Chief Carmen Best joins board to ensure the advancement of ethical AI technology in law enforcement

PR Newswire

SEATTLE, Dec. 10, 2020 /PRNewswire/ — Axon (Nasdaq: AAXN), the global leader in connected public safety technologies, today announced the appointment of Carmen Best, former Seattle police chief, to Axon’s AI Ethics Board.

“I admire Axon’s commitment to developing ethical AI technologies, especially examining how it impacts communities of color,” says Chief Best, who rose through the ranks through a nearly 30-year policing career to become the first black woman to lead Seattle’s police force. “I support the responsible development and deployment of AI technologies to improve community safety and improve how police work with communities.”

Best holds a distinguished career of public safety and transparency within Seattle’s Police department. As chief of police, Best championed diversity reforms, public safety, and gender equality. She fostered record-breaking women and diversity hiring and recruitment and is widely recognized for her dedication to justice and community. In addition to her service to Seattle’s communities, she is also a U.S. Army veteran, having served three years in South Korea.

Axon is proud to be developing products that address some of society’s most entrenched problems. As a leading technology company for law enforcement, Axon believes it has the obligation to do so in a responsible way — one that promotes transparency, with built in mechanisms for accountability. Axon’s AI and Policing Technology Ethics Board provides expert guidance to Axon on the development of its AI products and services, paying particular attention to its impact on communities. This diverse board includes leaders in the industry as well as some of the nation’s most well-known thought leaders and legal scholars regarding policing, police reform, technology, racial equity and civil liberties.

For more information on the AI and Policing Technology Ethics Board, please visit: www.axon.com/ethics.

About Axon

Axon is a network of devices, apps and people that helps public safety personnel become smarter and safer. With a mission of protecting life, our technologies give customers the confidence, focus and time they need to keep their communities safe. Our products impact every aspect of a public safety officer’s day-to-day experience.

We work hard for those who put themselves in harm’s way for all of us. To date, there are more than 300,000 software seats booked on the Axon network around the world and more than 242,000 lives and countless dollars have been saved with the Axon network of devices, apps, and people. Learn more at www.axon.com or by calling (800) 978-2737.

Facebook is a trademark of Facebook, Inc., and Twitter is a trademark of Twitter, Inc. Axon, and the Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Follow Axon here:

Note to Investors

Please visit http://investor.axon.com, https://www.axon.com/press, www.twitter.com/axon_us and https://www.facebook.com/Axon.ProtectLife/ where Axon discloses information about the company, its financial information and its business.

Visit our Investor Relations Safe Harbor Statement at: http://investor.axon.com/safeHarbor.cfm

CONTACT:

Sydney Siegmeth

VP, Global Communications
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/former-seattle-police-chief-to-join-axons-ai-ethics-board-promoting-responsible-development-of-ai-technologies-301190202.html

SOURCE Axon

Posted on

First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma

Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage repair

ST. HELIER, Jersey–(BUSINESS WIRE)–
Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma (GBM) testing the potential survival benefit of initiating Optune concurrent with radiation therapy.

Currently, Optune with maintenance temozolomide is used to treat adults with glioblastoma, following maximal debulking surgery and completion of radiation therapy. However, preclinical studies demonstrate Tumor Treating Fields can be used synergistically with radiation therapy, due to increased tumor sensitivity to radiation therapy, further inhibiting DNA damage repair.

Trident will enroll 950 newly diagnosed GBM patients who, after surgery or biopsy, are candidates for radiation therapy and temozolomide. The experimental group will receive Optune concurrent with radiation therapy and temozolomide for six weeks, followed by Optune and temozolomide. The control group will receive radiation therapy and temozolomide for six weeks, followed by Optune and temozolomide. Patients will continue on Optune for 24 months or until second tumor progression, whichever occurs first.

“We are excited to have begun our TRIDENT trial in newly diagnosed GBM,” said Dr. Ely Benaim, Novocure’s Chief Medical Officer. “The TRIDENT trial represents our commitment to extending survival for GBM patients. We look forward to our partnership with the hundreds of patients who will participate in this study, their families and caregivers, and the nearly 100 leading institutions who have committed to this important research in GBM.”

About Optune

Optune is a noninvasive, antimitotic cancer treatment for GBM. Optune delivers Tumor Treating Fields to the region of the tumor.

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division. Tumor Treating Fields does not stimulate or heat tissue and targets dividing cancer cells with specific membrane properties. Tumor Treating Fields causes minimal damage to healthy cells. Mild to moderate skin irritation is the most common side effect reported. Tumor Treating Fields is approved in certain countries for the treatment of adults with GBM and in the U.S. for MPM, two of the most difficult cancer types to treat. The therapy shows promise in multiple solid tumor types – including some of the most aggressive forms of cancer.

Approved Indications

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information

Contraindications

Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Use of Optune for GBM together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune for GBM in patients known to be sensitive to conductive hydrogels. Skin contact with the gel used with Optune may commonly cause increased redness and itching, and may rarely lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®.

The most common (≥10%) adverse events involving Optune in combination with chemotherapy in patients with GBM were thrombocytopenia, nausea, constipation, vomiting, fatigue, convulsions, and depression.

The most common (≥10%) adverse events related to Optune treatment alone in patients with GBM were medical device site reaction and headache. Other less common adverse reactions were malaise, muscle twitching, and falls related to carrying the device.

If the patient has an underlying serious skin condition on the treated area, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Investors:

Gabrielle Fernandes

[email protected]

603-206-7047

Media:

Jaclyn Stahl

[email protected]

212-767-7516

KEYWORDS: Jersey Europe

INDUSTRY KEYWORDS: Research Medical Devices FDA Clinical Trials Biotechnology Radiology Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo
Posted on

Temas Resources Announces Closing of $2.6 Million Flow-Through Financing at $1.00 per Share

Temas Resources Announces Closing of $2.6 Million Flow-Through Financing at $1.00 per Share

Laurentian Bank Securities Inc. acts as advisor to Temas Resources

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Temas Resources Corp. (the “Company” or “Temas Resources”, CSE: TMAS, OTCQB: TMASF), a publicly traded company focused on the advancement of mineral independence within stable, mining-friendly jurisdictions, announced today it has closed a private placement of 2,625,000 flow-through common shares (the “Shares”) at a price of $1.00 per Share for gross proceeds $2.625 million.

“Laurentian Bank Securities Inc.’ support of Temas Resources in the closing of this private placement at such a significant premium to the current share price confirms to us the market’s confidence in our company’s direction,” said Michael Dehn, CEO. “This $2.625 million financing is invaluable early-stage reinforcement of Temas Resources’ ability to achieve critical mining exploration objectives and execute on the vision and strategy we’ve put forth to date.”

The Private Placement is for an aggregate amount of CAD$2.625 million priced at $1.00 per Share. The Company intends to utilize the proceeds for mining exploration purposes in the province of Québec within 24 months.

“This Private Placement through Laurentian Bank Securities Inc. adds additional certainty to Temas Resources’ current corporate trajectory. The consistent support we’re beginning to see from financial institutions is allowing Temas Resources to continue to accelerate its rate of development,” Michael Dehn continued. “We appreciate the vote of confidence shown in the Private Placement market valuation of $1.00 per share, affirming we are taking Temas Resources’ leadership, mission, and ongoing operations in the right direction.”

Temas Resources has paid Laurentian Bank Securities Inc. (“Laurentian Bank”) a cash finder’s fee in an amount equal to 7% of the gross proceeds of the Private Placement. In addition, Temas Resources has issued non-transferable share purchase warrants priced at $1.00 equal to 7% of the aggregate number of Shares purchased to Laurentian Bank.

About Laurentian Bank Securities Inc.

Laurentian Bank Securities Inc. is an integrated full-service investment dealer, focusing on six lines of business. The well-respected Institutional fixed income division has a strong presence in Government and Corporate underwritings, as well as in secondary markets. In addition, the Institutional equity division focuses on serving clients through research, trading and investment banking in the small capitalization sector. The fast-growing Retail division and Discount Brokerage division currently serve clients through 13 offices in Québec. Furthermore, as a carrying broker, LBS provides complete back office support to a wide range of customers. LBS also offers the Immigrant Investors program. In the institutional market as in the retail market, Laurentian Bank Securities Inc. places above all, its expertise, experience, and sense of innovation to ensure its position and bring added-value to all of its activities.

About Temas Resources

Temas Resources Corp. (“Temas Resources“) (CSE: TMAS) (OTCQB: TMASF) is responding to the growing global demand for iron ore and two strategically important minerals — titanium and vanadium — deemed by the U.S. Department of the Interior as critical to U.S. national security and the economy. Temas Resources properties are located in the stable, mining-friendly jurisdiction of Quebec (Canada) bordering Vermont, Maine, and New York State (U.S.) in an area known as the Grenville Geological Province. The Grenville Geological Province is home to Lac Tio, the largest solid ilmenite deposit in the world. As a mineral exploration company focused on the acquisition, exploration and development of iron, titanium, and vanadium properties, Temas Resources has focused its efforts on advancing two major projects in the Grenville Geological Province area. The Company’s first project, the DAB Property, consists of an option for 100% interest on 128 contiguous mineral claims which covers 6,813 hectares (68.14 km²) within the Grenville Geological Province. At the Company’s flagship La Blache Property, Temas has 100% ownership of 48 semi-contiguous mineral claims which cover 2,653 hectares (26.53 km²) within the Grenville Geological Province. All public filings for the Company can be found on the SEDAR website www.sedar.com. For more information about the Company, please visit www.temasresources.com.

On behalf of the Board of Directors of Temas Resources Corp.,

“Kyler Hardy”

Director

Forward Looking Statements

This news release includes certain “Forward‐Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward‐looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward‐looking statements or information.

Forward‐looking statements and forward‐looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Temas Resources, future growth potential for Temas Resources and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of iron, titanium, vanadium and other metals; no escalation in the severity of the COVID-19 pandemic; costs of exploration and development; the estimated costs of development of exploration projects; Temas Resources’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

These statements reflect Temas Resources’ respective current views with respect to future events and are necessarily based upon a number of other assumptions and estimates that, while considered reasonable by management, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward‐looking statements or forward-looking information and Temas Resources has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the Company’s dependence on one mineral project; precious metals price volatility; risks associated with the conduct of the Company’s mining activities in Quebec; regulatory, consent or permitting delays; risks relating to reliance on the Company’s management team and outside contractors; risks regarding mineral resources and reserves; the Company’s inability to obtain insurance to cover all risks, on a commercially reasonable basis or at all; currency fluctuations; risks regarding the failure to generate sufficient cash flow from operations; risks relating to project financing and equity issuances; risks and unknowns inherent in all mining projects, including the inaccuracy of reserves and resources, metallurgical recoveries and capital and operating costs of such projects; contests over title to properties, particularly title to undeveloped properties; laws and regulations governing the environment, health and safety; the ability of the communities in which the Company operates to manage and cope with the implications of COVID-19; the economic and financial implications of COVID-19 to the Company; operating or technical difficulties in connection with mining or development activities; employee relations, labour unrest or unavailability; the Company’s interactions with surrounding communities and artisanal miners; the Company’s ability to successfully integrate acquired assets; the speculative nature of exploration and development, including the risks of diminishing quantities or grades of reserves; stock market volatility; conflicts of interest among certain directors and officers; lack of liquidity for shareholders of the Company; litigation risk; and the factors identified under the caption “Risk Factors” in Temas Resources’ management discussion and analysis. Readers are cautioned against attributing undue certainty to forward‐looking statements or forward-looking information. Although Temas Resources has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be anticipated, estimated or intended. Temas Resources does not intend, and does not assume any obligation, to update these forward‐looking statements or forward-looking information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements or information, other than as required by applicable law.

Nick Spencer, Investor Relations

Phone: +1 (604) 332-0902

Email: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Posted on

Tenet to Acquire Portfolio of Surgery Centers from SurgCenter Development

Tenet to Acquire Portfolio of Surgery Centers from SurgCenter Development

Expands USPI ambulatory business in line with Tenet’s stated strategy

Addition of up to 45 SCD centers cements Tenet’s position as preeminent national musculoskeletal services leader across care continuum

Investment in lower cost of care, highly efficient, consumer-friendly facilities that improve healthcare affordability and access

Enhances Tenet’s overall business mix and earnings profile

Management will host a conference call today, Dec. 10, at 8:30 a.m. Eastern Time, to discuss the transaction

DALLAS–(BUSINESS WIRE)–
Tenet Healthcare Corporation (NYSE: THC) today announced that it will acquire a portfolio of up to 45 ambulatory surgery centers (ASCs) (the “Portfolio”) from SurgCenter Development (SCD). The Portfolio will be operated by Tenet’s United Surgical Partners International (USPI) subsidiary as part of its industry-leading ambulatory surgery platform.

SCD, founded in 1993, is a leading developer of physician-owned ASCs with a history of establishing high-quality centers in partnership with physicians with demonstrated leadership in musculoskeletal surgeries. The 45 centers are located in Arizona, Florida, Indiana, Louisiana, Maryland, Ohio, New Hampshire, Texas and Wisconsin.

Under the terms of the transaction, the Company will purchase majority interests in up to 45 centers by fully acquiring SCD’s interests, and partially acquiring interests from physician partners, for approximately $1.1 billion in cash and the assumption of approximately $18 million of center-level debt.

USPI’s ownership interest will be up to 60 percent in each center, with the remainder owned by physician partners. Tenet will consolidate the financial results of the Portfolio within its Ambulatory Care segment with the exception of two centers in which USPI will own a minority interest. Tenet has completed the acquisition of a majority of the 45 centers and expects to complete the acquisition of the remainder of the Portfolio by the end of 2020, pending the finalization of documentation and the receipt of certain state approvals.

Ron Rittenmeyer, Tenet’s Executive Chairman and CEO, said, “This is a transformative transaction within our stated strategy to expand our ambulatory platform. It will enhance our overall business mix and further diversify our earnings profile by accelerating our shift toward lower cost of care, consumer-friendly, faster-growing assets for Tenet, USPI and our physician and health system partners. The transaction is a testament to the caliber and quality of the SCD facilities, physicians and staff, USPI’s incredible performance, and both organizations’ quick recovery relative to the pandemic.”

Dr. Gregory George, Co-Founder of SurgCenter, stated, “SCD is very pleased to complete this transaction with USPI, marking another milestone in our longstanding relationship. Following prior transactions with USPI, we consistently received strong positive feedback from our former physician partners who subsequently worked with USPI to continue to build and grow partnerships that we had developed together. The history between the companies made this transaction a natural evolution for many of our current physician partners and their facilities, enabling them to leverage the breadth and depth of both USPI and Tenet. We look forward to seeing the further growth and success of these partnerships while we continue to focus on the development of additional de novo facilities.”

Brett Brodnax, USPI’s President and CEO, said, “We acquired our first ASCs from SCD in 2005 and have built a longstanding and successful relationship. We have a tremendous amount of respect for SCD as one of the leading developers of ambulatory surgical facilities in the country. We are honored to be partnering with the high-quality physicians and staff who have an excellent track record of delivering patient-centered care with great outcomes in the communities they serve. The Portfolio will be an excellent complement to our national footprint of ambulatory surgical facilities, and we expect a seamless integration.”

Strategic Benefits of the Transaction

Creates largest musculoskeletal (“MSK”) surgery platform with national scale. Through the transaction, Tenet will become the leading provider of high-growth MSK surgeries across the care continuum, far surpassing others in the sector. Pending completion of the transaction, USPI’s surgical portfolio will have as many as 310 ambulatory surgical facilities, including 24 surgical hospitals, in 33 states. It will expand USPI’s established footprint in high-growth states, while amplifying scale in existing and/or new markets.

Portfolio consists of top-quality, physician-owned facilities which have generated strong growth and recovery from COVID-19. Comprised of high-quality centers with minimal facility-level debt, the Portfolio includes relatively young facilities with an average age of seven years. The Portfolio has over 800 medical staff physicians and a case mix weighted heavily toward high-growth MSK procedures in a lower cost-of-care setting, with approximately 80 percent attributed to orthopedics, pain and spine.

Cements strategic “partner of choice” reputation for ambulatory development, building on USPI’s 20+-year track record of operational excellence, integration and synergy capture. The Portfolio includes a roster of world-class physician partners, reinforcing USPI’s culture of collaborative development with physicians. USPI has a long history of acquiring, integrating and successfully growing SCD centers together with premier physicians, which provides opportunities for continued expansion of these partnerships. As a leader in terms of quality, relationships and capabilities, the enhanced USPI platform will have close to 5,000 physician partners and over 50 health system partners.

Attractive financial profile with immediate and significant EPS accretion and further EBITDA diversification. Tenet expects thetransaction to generate double-digit returns on invested capital within three years of completion, along with approximately 28 percent accretion to earnings per share in 2021. The transaction will further diversify Tenet’s Adjusted EBITDA with approximately 42 percent expected to be generated by the Company’s ambulatory business in 2021, up significantly from 4 percent in 2014 prior to Tenet’s acquisition of a majority stake in USPI. The Company expects to realize approximately $40 million to $50 million of annual run-rate synergies over the next three years.

Acquisition financed with balance sheet cash. The transaction will be fully funded with cash from Tenet’s balance sheet separate from grant funds that have been received as a result of the Coronavirus Aid, Relief and Economic Security (CARES) Act. In addition, the transaction is expected to be leverage neutral, and Tenet remains committed to continued deleveraging over time.

Goldman Sachs & Co LLC acted as financial advisor to Tenet, and Willkie Farr & Gallagher LLP served as legal counsel.

Management’s Webcast Discussion of the Transaction

Tenet management will discuss this transaction on a webcast scheduled for 8:30 a.m. Eastern Time (7:30 a.m. Central Time) today, Dec. 10, 2020. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors. The slide presentation associated with the webcast referenced above and a copy of this press release are available on the Company’s Investor Relations website. A replay of the webcast will be available on Tenet’s website for approximately 30 days.

Cautionary Statement

This release contains “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements address our expectations of the benefits and synergies of the acquisition and the performance of the centers in the Portfolio, as well as the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain, especially with regards to developments related to COVID-19, and are subject to numerous risks and uncertainties, many of which are outside of our control. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to, the ability to close and successfully integrate the operations of the acquired centers into our enterprise; the ability to recognize the anticipated benefits of the acquisition, which may be affected by, among other things, competition, regulation, our ability to grow profitably and maintain relationships with physicians and key healthcare system partners; the risk that the acquisition disrupts current plans and operations of our enterprise and/or the acquired centers; the impact of the COVID-19 pandemic and the other factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2019, subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas with 110,000 employees. Through an expansive care network that includes United Surgical Partners International, we operate 65 hospitals and more than 520 other healthcare facilities, including surgical hospitals, ambulatory surgery centers, urgent care and imaging centers and other care sites and clinics. We also operate Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other customers. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Investor Contact

Regina Nethery

469-893-2387

[email protected]

Media Contact

Lesley Bogdanow

469-893-2640

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Hospitals Health Surgery Practice Management

MEDIA:

Logo
Logo
Posted on

Waters Corporation Appoints Pearl S. Huang to Board of Directors

Waters Corporation Appoints Pearl S. Huang to Board of Directors

MILFORD, Mass.–(BUSINESS WIRE)–
Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005237/en/

Dr. Pearl S. Huang (Photo: Business Wire)

Dr. Pearl S. Huang (Photo: Business Wire)

“We are pleased to welcome Pearl to the Waters Board of Directors,” said Dr. Flemming Ornskov, Chairman of the Board. “Pearl is a distinguished executive with significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as a proven track record in drug discovery and the development of clinical trials. We look forward to benefitting from Pearl’s perspectives and believe she will add even greater value to Waters’ distinguished board of scientists and business leaders.”

“Pearl brings a tremendous blend of scientific expertise, global experience and an entrepreneurial spirit that is vital for Waters as we look to grow our product and services footprint in both pharmaceutical and clinical laboratories around the world,” said Dr. Udit Batra, CEO and President, Waters Corporation. “We are very fortunate to have Pearl join us and I look forward to working with her on our journey ahead.”

“Waters holds an essential position as a pioneering innovator whose products and services enable essential innovation in the life, food and materials sciences,” said Dr. Huang. “I’m honored and excited to work with the Board as well as Udit and the leadership team to leverage my experience to help Waters pursue opportunities for growth in the burgeoning pharma and biopharma industries.”

Dr. Huang is President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering. She currently serves on the boards of Cygnal Therapeutics and KSQ Therapeutics. She previously held senior roles within the pharmaceutical industry, including Senior Vice President and Global Head of Therapeutic Modalities at Roche and Vice President and Global Head of Discovery Academic Partnerships at GSK. Dr. Huang co-founded BeiGene in 2010 and served as its Chief Scientific Officer. Before BeiGene, she led teams in oncology discovery at both Merck and GSK. She has received multiple awards and recognitions throughout her career. In 2020, Dr. Huang was named to the PharmaVOICE 100, a list of the most inspiring leaders in the life sciences, and was featured by FiercePharma as one of the Fiercest Women in Life Sciences. She received her undergraduate degree in life sciences from the Massachusetts Institute of Technology and a Ph.D. in molecular biology from Princeton University.

Additional Resources

About Waters Corporation

Waters Corporation (NYSE:WAT), the world’s leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,000 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events, including statements regarding Dr. Huang’s appointment. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “will,” “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects”, and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Actual future results and events may differ significantly from the results and events discussed in the forward-looking statements within this release for a variety of reasons, including the factors that are discussed in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission (“SEC”), as updated by the Company’s subsequent filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

Kevin Kempskie

Corporate Communications

Waters Corporation

[email protected]

617-413-4333

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Science Other Science Research

MEDIA:

Logo
Logo
Photo
Photo
Dr. Pearl S. Huang (Photo: Business Wire)
Posted on

Mogo Announces Early Conversion of Convertible Debentures & Date of Special Shareholder Meeting to Approve Acquisition of Carta Worldwide

Mogo Announces Early Conversion of Convertible Debentures & Date of Special Shareholder Meeting to Approve Acquisition of Carta Worldwide

  • Conversion of debentures will result in strengthened balance sheet and reduced interest expense going forward
  • On track to close previously announced acquisition of digital payments company, Carta Worldwide, by the end of January 2021 with special shareholder meeting scheduled for January 15, 2021
  • Mogo had more than $26M of cash & investment portfolio at the end of the most recent quarter providing the company with significant financial flexibility

All figures in Canadian $

VANCOUVER, British Columbia–(BUSINESS WIRE)–Mogo Inc. (TSX:MOGO) (NASDAQ:MOGO) (“Mogo” or the “Company”), a financial technology company focused on empowering consumers with innovative digital financial solutions through its mobile app, today announced that it will be giving notice to holders of its 10.0% convertible senior secured debentures due May 31, 2022 (TSX: MOGO.DB) (the “Convertible Debentures“) that such Convertible Debentures will be converted into common shares of Mogo (“Shares”) on or about January 11, 2021 (the “Conversion Date”).

Under the terms of the indenture relating to the Convertible Debentures, at any time that the 20-day volume weighted average trading price (“VWAP”) of the Shares on the TSX exceeds $3.4375 per Share, the Company may convert the Convertible Debentures in whole or in part, including any accrued and unpaid interest, to Shares. Subject to the terms of the indenture relating to the Convertible Debentures, the principal amount of the Convertible Debentures shall convert at $2.75 per Share and, subject to TSX approval, the accrued and unpaid interest on such Convertible Debentures shall convert at the greater of (i) the 20-day VWAP of the Shares on the fifth trading day prior to the Conversion Date and (ii) the maximum discount permitted by the rules of the TSX, less any taxes required to be deducted therefrom.

“We have taken multiple meaningful steps to improve our profitability and our balance sheet in 2020, and this early conversion will further simplify our capital structure moving forward,” said Greg Feller, President and Chief Financial Officer of Mogo. “As we transition back to growth mode heading into 2021, we are financially well positioned.”

Currently there is an aggregate principal amount of approximately $10.9 million of Convertible Debentures outstanding.

The Company also announced that it will hold a special meeting of shareholders to approve its previously announced acquisition of Carta Solutions Holding Corporation, also know as Carta Worldwide, on January 15, 2021.

Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of applicable securities legislation, including statements regarding the conversion of the Convertible Debentures and the number of Shares issued upon such conversion, the effect of the conversion on Mogo’s balance sheet and interest expense and the anticipated closing of Mogo’s previously announced acquisition of Carta Worldwide. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at the time of preparation, are inherently subject to significant business, economic and competitive uncertainties and contingencies, and may prove to be incorrect. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Mogo’s growth, its ability to expand into new products and markets and its expectations for its future financial performance are subject to a number of conditions, many of which are outside of Mogo’s control. For a description of the risks associated with Mogo’s business please refer to the “Risk Factors” section of Mogo’s current annual information form, which is available at www.sedar.com and www.sec.gov. Except as required by law, Mogo disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise.

About Mogo

Mogo — a financial technology company — offers a finance app that empowers consumers with simple solutions to help them get in control of their financial health and be more mindful of the impact they have on society and the planet. Users can sign up for a free account in only three minutes, begin to learn the 4 habits of financial health and get convenient access to products that can help them achieve their financial goals and have a positive impact on the planet including a digital spending account with Mogo Visa* Platinum Prepaid Card featuring automatic carbon offsetting, free monthly credit score monitoring, ID fraud protection and personal loans. Members can also easily buy and sell bitcoin 24/7 through the Mogo app, as well as participate in Mogo’s new bitcoin rewards program. The Mogo platform has been purpose-built to deliver a best-in-class digital experience, with best-in-class products, all through one account. With more than one million members and a marketing partnership with Canada’s largest news media company, Mogo continues to execute on its vision to gamify financial health and become the go-to financial app for the next generation of Canadians. To learn more, please visit mogo.ca or download the mobile app (iOS or Android).

Craig Armitage

Investor Relations

[email protected]

(416) 347-8954

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Other Professional Services Software Finance Banking Data Management Professional Services Technology Mobile/Wireless

MEDIA:

Posted on

Fiserv Announces Pricing of Secondary Offering of Common Stock by New Omaha Holdings and Associated Repurchase of its Common Stock

Fiserv Announces Pricing of Secondary Offering of Common Stock by New Omaha Holdings and Associated Repurchase of its Common Stock

BROOKFIELD, Wis.–(BUSINESS WIRE)–Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, announced today the pricing of the previously announced underwritten public offering of 17,500,000 shares of the company’s common stock by New Omaha Holdings L.P. (“New Omaha”), which is owned by investment funds managed by Kohlberg Kravis Roberts & Co. L.P., at a price of $112.00 per share (the “offering”). In addition, New Omaha has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of the company’s common stock at the public offering price, less underwriting discounts and commissions. Fiserv is not selling any shares in, nor will it receive any proceeds from, the offering. New Omaha will receive all of the net proceeds from the offering. The offering is expected to close on December 11, 2020, subject to customary closing conditions.

Subject to the completion of the offering, Fiserv has agreed to repurchase from the underwriters 1,817,520 shares of the company’s common stock that are subject to the offering at a price per share equal to the price per share to be paid by the underwriters to New Omaha in the offering (the “share repurchase”). Fiserv intends to fund the share repurchase with cash on hand. The repurchased shares will be cancelled and no longer outstanding following the completion of the share repurchase.

Prior to the proposed offering, New Omaha owned 105,425,667 shares of common stock, representing approximately 15.7% of Fiserv’s outstanding shares of common stock, based on the number of shares outstanding as of October 23, 2020. Upon completion of the proposed offering, New Omaha is expected to own shares of common stock representing approximately 13.1% (or approximately 12.7% if the underwriters exercise their option to purchase additional shares in full) of Fiserv’s outstanding shares of common stock, based on the number of shares outstanding as of October 23, 2020. The number of shares outstanding as of October 23, 2020 does not include any issuances or repurchases after such date, including the share repurchase.

BofA Securities, Citigroup Global Markets Inc., KKR Capital Markets LLC, PNC Capital Markets LLC, Truist Securities, Inc., Wells Fargo Securities, Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, BMO Capital Markets Corp., Mizuho Securities USA LLC, Barclays, Credit Suisse Securities (USA) LLC, HSBC Securities (USA) Inc., Goldman Sachs & Co. LLC and SPC Capital Markets LLC are acting as joint bookrunners managers. Keefe, Bruyette & Woods, Inc., WR Securities, LLC and KeyBanc Capital Markets Inc., Loop Capital Markets LLC, Guzman & Company, Tigress Financial Partners and Roberts & Ryan Investments, Inc. are acting as bookrunners.

Fiserv filed an automatically effective shelf registration statement (including a prospectus, File No. 333-227436) on September 20, 2018, with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before making any investment decision, you should read the prospectus in that registration statement and other documents that the company has filed with the SEC and are incorporated by reference in the registration statement for more complete information about Fiserv and the offering. The offering is being made solely by means of a prospectus. Fiserv has filed a preliminary prospectus supplement and intends to file a further prospectus supplement with respect to the offering. You may obtain copies of these documents by contacting BofA Securities, NC1-004-03-43 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department or by email to [email protected]; Citigroup Global Markets, Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 800-831-9146 or by email to [email protected]; or KKR Capital Markets LLC by telephone at (212) 750-8300 or by email to [email protected]. An electronic copy of the prospectus and prospectus supplement is available from the SEC website at http://www.sec.gov.

This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Nothing in this press release should be construed as an offer to sell, or the solicitation of an offer to buy, any securities subject to the share repurchase.

About Fiserv

Fiserv, Inc. (NASDAQ: FISV) aspires to move money and information in a way that moves the world. As a global leader in payments and financial technology, the company helps clients achieve best-in-class results through a commitment to innovation and excellence in areas including account processing and digital banking solutions; card issuer processing and network services; payments; e-commerce; merchant acquiring and processing; and the Clover® cloud-based point-of-sale solution. Fiserv is a member of the S&P 500® Index and the FORTUNE® 500, and is among FORTUNE World’s Most Admired Companies®.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those that express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression, and can generally be identified as forward-looking because they include words such as “believes,” “anticipates,” “expects,” “could,” “should,” or words of similar meaning. Statements that describe the company’s future plans, objectives or goals are also forward-looking statements.

Forward-looking statements are subject to assumptions, risks and uncertainties that may cause actual results to differ materially from those contemplated by such forward-looking statements. The factors that may affect the company’s results materially include, among others, the following, many of which are, and will be, amplified by the COVID-19 pandemic: the duration and intensity of the COVID-19 pandemic; governmental and private sector responses to the COVID-19 pandemic and the impact of such responses on the company; the impact of the COVID-19 pandemic on the company’s employees, clients, vendors, operations and sales; the possibility that the company may be unable to achieve expected synergies and operating efficiencies from the acquisition of First Data Corporation (“First Data”) within the expected time frames or at all or to successfully integrate the operations of First Data into the company’s operations; such integration may be more difficult, time-consuming or costly than expected; profitability following the transaction may be lower than expected, including due to unexpected costs, charges or expenses resulting from the transaction; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the transaction; unforeseen risks relating to the company’s liabilities or those of First Data may exist; the company’s ability to meet expectations regarding the accounting and tax treatments of the transaction; the company’s ability to compete effectively against new and existing competitors and to continue to introduce competitive new products and services on a timely, cost-effective basis; changes in customer demand for the company’s products and services; the ability of the company’s technology to keep pace with a rapidly evolving marketplace; the successful management of the company’s merchant alliance program which involves several alliances not under its sole control; the impact of a security breach or operational failure on the company’s business including disruptions caused by other participants in the global financial system; the failure of the company’s vendors and merchants to satisfy their obligations; the successful management of credit and fraud risks in the company’s business and merchant alliances; changes in local, regional, national and international economic or political conditions and the impact they may have on the company and its customers; the effect of proposed and enacted legislative and regulatory actions affecting the company or the financial services industry as a whole; the company’s ability to comply with government regulations and applicable card association and network rules; the protection and validity of intellectual property rights; the outcome of pending and future litigation and governmental proceedings; the company’s ability to successfully identify, complete and integrate acquisitions, and to realize the anticipated benefits associated with the same; the impact of the company’s strategic initiatives; the company’s ability to attract and retain key personnel; volatility and disruptions in financial markets that may impact the company’s ability to access preferred sources of financing and the terms on which the company is able to obtain financing or increase its costs of borrowing; adverse impacts from currency exchange rates or currency controls; and other factors identified in the company’s Annual Report on Form 10-K for the year ended December 31, 2019, the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and in other documents that the company files with the SEC, which are available at http://www.sec.gov. You should consider these factors carefully in evaluating forward-looking statements and are cautioned not to place undue reliance on such statements. The company assumes no obligation to update any forward-looking statements, which speak only as of the date of this news release.

FISV-G

Media Relations:

Britt Zarling

Corporate Communications

Fiserv, Inc.

414-378-4040

[email protected]

Investor Relations:

Peter Poillon

Investor Relations

Fiserv, Inc.

212-266-3565

[email protected]

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Technology Finance Software Banking

MEDIA:

Logo
Logo
Posted on

Applied Materials Announces 2020 Supplier Excellence Awards

SANTA CLARA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced the recipients of its 2020 Supplier Excellence Awards for contributions made to Applied’s business over the past year. The awards reflect outstanding technical and operational performance in several areas including quality, service, lead time, delivery, cost and responsiveness.

“This past year more than any other has shown the importance of having a resilient and agile supply chain,” said Dr. Gino Addiego, senior vice president of Engineering, Operations and Quality at Applied Materials. “I want to thank all our suppliers, especially our 2020 Supplier Excellence Award recipients, for helping Applied Materials fulfill our customer commitments and deliver innovative materials engineering solutions to the industry.”

The following 11 companies received Supplier Excellence Awards in their designated categories for consistently meeting or exceeding Applied’s performance expectations over the past year:

Best in Class Performance

ETLA Limited
Foxsemicon Integrated Technology Inc.
Richport Technology
SINFONIA TECHNOLOGY CO., LTD
THERM-X

Excellence in Aftermarket Support

NTK Technologies, Inc.
Tokai Carbon Korea

Excellence in Innovation and New Product Support 

FM Industries, Inc. an NGK Group Company
NorCal Engineering Inc.
TRUMPF Huettinger

Excellence in Quality

Chenfull International CO., Ltd.

About Applied Materials

Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions used to produce virtually every new chip and advanced display in the world. Our expertise in modifying materials at atomic levels and on an industrial scale enables customers to transform possibilities into reality. At Applied Materials, our innovations make possible the technology shaping the future. Learn more at www.appliedmaterials.com.

Contact:

Ricky Gradwohl (editorial/media) 408.235.4676
Michael Sullivan (financial community) 408.986.7977



Posted on

Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics

The first
Mydecine
Speaker Series event will feature
Mydecine
Scientific Advisory Board Members Dr. Robin
Carhart
-Harris and Dr. Ruth
Lanius
, Chief Medical Officer Rakesh
Jetly
and Chief Scientific Officer Robert
Roscow

Moderated by
Yeji
Lee, Business Insider reporter, the panelists will discuss the impact of cutting edge research in mainstream medical interest about unlocking the potential of psychedelic therapies

Robert
Roscow
, Chief Science Officer of
Mydecine
to be named to
Mydecine
Board of Directors

DENVER, Dec. 10, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced today that the Company has partnered with Microdose Psychedelic Insights (“Microdose”), a leader in B2B psychedelic intelligence, to present a free, three-part live video discussion series titled “Mydecine Speaker Series” covering Research, Psychedelic Therapies, PTSD, Microdosing, and Drug Discovery.

Details and schedule of the first event are as follows:

Title:
 How cutting edge research is igniting mainstream medical interest to unlock the potential of psychedelic therapies
   
Panel: -Dr. Robin Carhart-Harris, Head of the Centre for Psychedelic Research, Division of Brain Sciences, Faculty of Medicine, Imperial College London

-Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, Chief Medical Officer, Mydecine Innovations Group

-Dr. Ruth Lanius, MD, PhD, Professor of Psychiatry and the director of the post-traumatic stress disorder (PTSD) research unit at the University of Western Ontario

-Robert Roscow, MA, Chief Science Officer & Co-Founder of Mydecine Innovations Group, Former head of genetic research for Canopy Growth and prior was the head of genetics at ebbu
   
Moderator:
 Yeji Lee, Business Insider
   
Date:
 December 15, 2020 at 12:00 p.m. – 1:30 p.m. Eastern
   
Registration site: bit.ly/3guDU5v

“We are excited to introduce members of our Management and Scientific Advisory Board and give some insight into the incredible projects and direction they are focused on in this dynamic field.  As key thought leaders in the community, their insights to the audience will be highly educational. In breaking down these key issues in drug development and other advances in research, we are able to foster a lively, informed debate among those leaders who are helping to shape the psychedelic industry,” said Joshua Bartch, CEO of Mydecine. “The more resources that are available to key stakeholders in this industry, the more we will see wider public acceptance of these important – and in some cases – life changing compounds.”

In each webinar, 3 to 4 featured thought leaders in the psychedelic space will give their expert perspective on the current and future research, findings and their applications to the marketplace. The participants will engage in deep and intimate conversations followed by a Q&A period with the audience. 

We would also like to welcome Robert Roscow, CSO, to the Board of Directors for Mydecine Innovations Group.  As one of the founders, his background and knowledge to help drive the vision for Mydecine is invaluable. His expertise and contributions around genomics, evolution and molecular biology around cannabinoids were key drivers to the success of ebbu and Canopy Growth. His work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his focus on the vast healing potential of the safe and effective compounds found in fungi. 


About


Mydecine


Innovations Group

 

Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada. 

Learn more at: https://www.mydecine.com and follow us on Facebook, Twitter, and Instagram.

Mydecine
Innovations Group Media Contacts:

Anne Donohoe / Nick Opich
KCSA Strategic Communications
[email protected] / [email protected] 
212-896-1265 / 212-896-1206

On behalf of the Board of Directors
:

Joshua Bartch, Chief Executive Officer
[email protected]

Corp Communication
:

Charles Lee, Investor Relations
[email protected]
+1 720-277-9879

For further information about
Mydecine
Innovations Group, Inc., please visit the Company’s profile on SEDAR at

www.sedar.com

or visit the Company’s website at

www.mydecine.com

.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.